Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR1019A and BR1019B Combination Therapy in Essential Hypertension and Type 2 Diabetes Mellitus
NCT06220773Phase 3Recruiting
- Sponsor
- Boryung
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of BR1019, BR1019B in essential hypertension, type 2 diabetes mellitus (T2DM), sponsored by Boryung. Started May 2024; status: recruiting.
02
Drugs
BR1019BR1019B
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06220773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06220773.